<VariationArchive VariationID="38260" VariationName="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs)" VariationType="Deletion" Accession="VCV000038260" Version="93" RecordType="classified" NumberOfSubmissions="27" NumberOfSubmitters="26" DateLastUpdated="2024-07-29" DateCreated="2014-04-01" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="46816" VariationID="38260">
      <GeneList>
        <Gene Symbol="BRCA2" FullName="BRCA2 DNA repair associated" GeneID="675" HGNC_ID="HGNC:1101" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32315508" stop="32400268" display_start="32315508" display_stop="32400268" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32889616" stop="32973808" display_start="32889616" display_stop="32973808" Strand="+" />
          </Location>
          <OMIM>600185</OMIM>
          <Haploinsufficiency last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2022</Property>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
        </Gene>
      </GeneList>
      <Name>NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs)</Name>
      <CanonicalSPDI>NC_000013.11:32398209:TGTATG:TG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>13q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32398210" stop="32398213" display_start="32398210" display_stop="32398213" variantLength="4" positionVCF="32398209" referenceAlleleVCF="TTGTA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32972347" stop="32972350" display_start="32972347" display_stop="32972350" variantLength="4" positionVCF="32972346" referenceAlleleVCF="TTGTA" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>NM_000059.4(BRCA2):c.9699_9702del</Name>
        <Name>p.Cys3233fs</Name>
        <Name>9927del4</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.3" sequenceAccession="NM_000059" sequenceVersion="3" change="c.9699_9702delTATG">
            <Expression>NM_000059.3:c.9699_9702delTATG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="U43746.1" sequenceAccession="U43746" sequenceVersion="1" change="n.9927_9930delTATG">
            <Expression>U43746.1:n.9927_9930delTATG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.32972349_32972352del" Assembly="GRCh37">
            <Expression>NC_000013.10:g.32972349_32972352del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.11" sequenceAccession="NC_000013" sequenceVersion="11" change="g.32398212_32398215del" Assembly="GRCh38">
            <Expression>NC_000013.11:g.32398212_32398215del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012772.3" sequenceAccession="NG_012772" sequenceVersion="3" change="g.87733_87736del">
            <Expression>NG_012772.3:g.87733_87736del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.4" sequenceAccession="NM_000059" sequenceVersion="4" change="c.9699_9702del" MANESelect="true">
            <Expression>NM_000059.4:c.9699_9702del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000050.3" sequenceAccession="NP_000050" sequenceVersion="3" change="p.Cys3233fs">
            <Expression>NP_000050.3:p.Cys3233fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_293" sequenceAccession="LRG_293">
            <Expression>LRG_293:g.87733_87736del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="9927&amp;base_change=del TATG" DB="Breast Cancer Information Core (BIC) (BRCA2)" />
        <XRef ID="CA026270" DB="ClinGen" />
        <XRef Type="rs" ID="80359775" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Breast-ovarian cancer, familial, susceptibility to, 2" Accession="RCV000031843" Version="29">
        <ClassifiedConditionList TraitSetID="2560">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2024-02-05" SubmissionCount="10">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Hereditary breast ovarian cancer syndrome" Accession="RCV000168365" Version="23">
        <ClassifiedConditionList TraitSetID="7920">
          <ClassifiedCondition DB="MedGen" ID="C0677776">Hereditary breast ovarian cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-03" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND not specified" Accession="RCV000200978" Version="20">
        <ClassifiedConditionList TraitSetID="9590">
          <ClassifiedCondition DB="MedGen" ID="CN169374">not specified</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-18" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND not provided" Accession="RCV000590308" Version="40">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
            <Description DateLastEvaluated="2023-03-01" SubmissionCount="6">Conflicting interpretations of pathogenicity</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Genetic non-acquired premature ovarian failure" Accession="RCV000770914" Version="9">
        <ClassifiedConditionList TraitSetID="47224">
          <ClassifiedCondition DB="MedGen" ID="C5816691">Genetic non-acquired premature ovarian failure</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2018-10-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000771139" Version="18">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-11-01" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Familial cancer of breast" Accession="RCV001262735" Version="11">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-03-27" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND Malignant tumor of breast" Accession="RCV001353983" Version="10">
        <ClassifiedConditionList TraitSetID="25616">
          <ClassifiedCondition DB="MedGen" ID="C0006142">Malignant tumor of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND BRCA2-related disorder" Accession="RCV004528146" Version="2">
        <ClassifiedConditionList TraitSetID="33530">
          <ClassifiedCondition DB="MedGen" ID="CN239275">BRCA2-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-18" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9699_9702del (p.Cys3233fs) AND BRCA2-related cancer predisposition" Accession="RCV004566790" Version="1">
        <ClassifiedConditionList TraitSetID="98005">
          <ClassifiedCondition DB="MedGen" ID="CN377758">BRCA2-related cancer predisposition</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2024-06-11" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-06-11" NumberOfSubmissions="27" NumberOfSubmitters="26" DateCreated="2014-04-01" MostRecentSubmission="2024-07-15">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16683254</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17026620</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18593900</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18607349</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22711857</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24549055</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25479140</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25639900</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25863477</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26633542</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27276934</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27352968</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28637432</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28888541</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29084914</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29161300</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29339979</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29446198</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29753700</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29875428</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29907814</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29922827</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29997359</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30630528</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30716324</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30720243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31658756</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31753525</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32393813</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32482800</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32719484</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32853339</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32939053</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33293522</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33753322</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33804961</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35260348</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35438911</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/597d0db5-c993-419b-8a7e-504098d8d901</URL>
        </Citation>
        <DescriptionHistory Dated="2024-02-03">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2023-11-10">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2016-09-23">
          <Description>Conflicting classifications of pathogenicity</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9590" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16789" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">AllHighlyPenetrant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not specified</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not specified' was created for use in ClinVar so that submitters can convey the concept that a variant is benign, likely benign, or of uncertain significance for an unspecified set of disorders.  This usage was introduced in 2014 to replace AllHighlyPenetrant.</Attribute>
              </AttributeSet>
              <XRef ID="CN169374" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2560" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33530" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="36472" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">BRCA2-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">BRCA2-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BRCA2-Related Disorders</ElementValue>
              </Name>
              <XRef ID="CN239275" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25616" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="34847" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of breast</ElementValue>
                <XRef ID="254837009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant breast neoplasm</ElementValue>
                <XRef ID="C9335" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer breast</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="pmc">2936467</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2018">
                <ID Source="PubMed">29939840</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">30452337</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2018">
                <URL>https://www.nice.org.uk/guidance/dg34</URL>
                <CitationText>Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®) Breast Cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="C0006142" DB="MedGen" />
              <XRef ID="MONDO:0007254" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="98005" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="76329" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">BRCA2-related cancer predisposition</ElementValue>
                <XRef ID="MONDO:0700269" DB="MONDO" />
              </Name>
              <XRef ID="CN377758" DB="MedGen" />
              <XRef ID="MONDO:0700269" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="47224" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="41621" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Genetic non-acquired premature ovarian failure</ElementValue>
              </Name>
              <XRef ID="485382" DB="Orphanet" />
              <XRef ID="C5816691" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7920" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16761" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer</ElementValue>
                <XRef ID="UWMG_4506306" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary breast ovarian cancer syndrome</ElementValue>
                <XRef ID="MONDO:0003582" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast and ovarian cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome (HBOC)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and/or ovarian cancer syndrome</ElementValue>
                <XRef ID="145" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome</ElementValue>
                <XRef ID="D061325" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HBOC</ElementValue>
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15010" />
                <XRef ID="15010" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512699" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502103" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595973" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508566" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508956" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508948" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551441" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520887" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521499" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561859" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503369" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523320" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C0677776" DB="MedGen" />
              <XRef ID="D061325" DB="MeSH" />
              <XRef ID="MONDO:0003582" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="376493" SubmissionDate="2019-01-29" DateLastUpdated="2019-04-17" DateCreated="2015-02-24">
        <ClinVarSubmissionID localKey="GDX:9065|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000210802" DateUpdated="2019-04-17" DateCreated="2015-02-24" Type="SCV" Version="13" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>This deletion of four nucleotides is denoted BRCA2 c.9699_9702delTATG at the cDNA level and p.Cys3233TrpfsX15 (C3233WfsX15) at the protein level. Using alternate nomenclature, this variant would be defined as 9927_9930delTATG or 9927del4. The normal sequence, with the bases that are deleted in brackets, is TTTG[delTATG]GCCA. The deletion causes a frameshift, which changes a Cysteine to a Tryptophan at codon 3233, and creates a premature stop codon at position 15 of the new reading frame. This variant has been observed in individuals with a personal and/or family history of breast and/or ovarian cancer, and in an individual with breast cancer who also carried a second BRCA2 frameshift variant (van der Hout 2006, Castera 2014, Kang 2015, Alemar 2017, Bunnell 2017, Grindedal 2017). BRCA2 c.9699_9702delTATG is predicted to result in a truncated protein that removes the nuclear localization signals, the Cyclin A binding domain, and part of the RAD51 binding domain (Esashi 2005, Borg 2010, Roy 2012). Although frameshift variants are typically considered pathogenic, this variant occurs just upstream of a well-known polymorphism that also results in a premature stop of translation (Lys3326Ter). In addition, this variant has been seen in trans with a known pathogenic BRCA2 variant in several individuals without classic features of Fanconi anemia and was not found to consistently segregate with cancer in other families harboring this variant (Rosenthal 2015). Despite the seemingly damaging nature of this variant and some evidence of pathogenicity, based on currently available and internal data, we consider this to be a variant of uncertain significance.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="264598" SubmissionDate="2014-03-28" DateLastUpdated="2014-04-01" DateCreated="2014-04-01">
        <ClinVarSubmissionID localKey="U43746.1:n.9927_9930delTATG|MedGen:C2675520" />
        <ClinVarAccession Accession="SCV000147700" DateUpdated="2014-04-01" DateCreated="2014-04-01" Type="SCV" Version="1" SubmitterName="Breast Cancer Information Core (BIC) (BRCA2)" OrgID="504197" OrganizationCategory="locus-specific database (LSDB)" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-05-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Latin American, Caribbean</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Western European, Native American, Centr</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>U43746.1:exon 27</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>9927del4</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="80359775" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">U43746.1:n.9927_9930delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1148747" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2017-08-27">
        <ClinVarSubmissionID localKey="chr13:32972345-32972350:6222533e1e3fa1954ef389eb5450ff76-BREAST" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000592303" DateUpdated="2021-04-13" DateCreated="2017-08-27" Type="SCV" Version="2" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>BRCA2, Exon 27, c.9699_9702delTATG, p.Cys3233TrpfsX15, Heterozygous, Uncertain Significance The BRCA2 p.Cys3233TrpfsX15 variant was identified in 1 of 862 proband chromosomes (frequency: 0.001) from individuals or families with hereditary breast and ovarian cancer (HBOC), and this study classifies this variant as deleterious (van der Hout 2006). The variant was also identified in dbSNP (ID: rs80359775) Ã¢â¬Å¡ÃâÃÂºWith pathogenic alleleÃ¢â¬Å¡ÃâÃÂ¹, Clinvitae database, ARUP Laboratories BRCA Mutations Database (as definitely pathogenic), the ClinVar database with conflicting classifications (pathogenic by Ambry Genetics and BIC, likely pathogenic by Counsyl and SCRP, and uncertain significance by GeneDX), and the BIC database (3X with clinical importance). In UMD the variant was classified as a causal variant, but it was also identified with a co-occurring pathogenic BRCA1 variant (p.Gln1327X), increasing the likelihood that the p.Cys3233TrpfsX15 variant does not have clinical significance. This variant was also identified in the Exome Aggregation Consortium (ExAC) database (released Jan 13, 2015) in 9 of 11534 chromosomes (frequency: 0.00078) from a population of Latino individuals, as well as at a much lower frequency in European (Non-Finnish) individuals, although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. Myriad published a case study on the pathogenicity of this variant (Rosenthal 2015). Although this variant is near the 3Ã¢â¬Å¡ÃâÃ¢â°Â¤ end of the BRCA2 gene, there are known pathogenic variants downstream of this position, i.e. c.9924C&gt;G (p.Tyr3308X), therefore this variant is expected to cause HBOC and would typically be classified as pathogenic. However, the Myriad study reports observations of the variant in trans with other deleterious BRCA2 variants in two sets of patients with no reported symptoms of Fanconi Anemia, and in two more individuals who also carry a pathogenic variant in BRCA2. The study further reports that they have detected this variant in 67 apparently unrelated individuals undergoing comprehensive analysis of BRCA1 and BRCA2. These observations currently meet the threshold for a benign designation. The study further states that family testing outcomes do not demonstrate consistent segregation of the variant with breast or ovarian cancer, although some contribution of the variant to the familial aggregation of cancer cannot be excluded. Therefore the Myriad study states that BRCA2 c.9699_9702del is currently reported as a Ã¢â¬Å¡ÃâÃÂ²special interpretation variantÃ¢â¬Å¡ÃâÃÂ´. The authors state that there is as yet no compelling hypothetical mechanism as to why BRCA2 c.9699_9702del is not causative of HBOC. They further conclude that it is important to note that the variant is not yet proven to have absolutely no impact on cancer risk, although the available data suggests that the risk falls far short of what is considered to be diagnostic of the associated clinical syndrome. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of Uncertain significance.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="0" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="T" referenceAllele="TTGTA" start="32972346" stop="32972350" variantLength="5" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007254" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4054620" SubmissionDate="2022-01-25" DateLastUpdated="2022-01-29" DateCreated="2022-01-29">
        <ClinVarSubmissionID localKey="NM_000059.3(BRCA2):c.9699_9702del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002067527" DateUpdated="2022-01-29" DateCreated="2022-01-29" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-08-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>DNA sequence analysis of the BRCA2 gene demonstrated a four base pair deletion in exon 27, c.9699_9702del. This sequence change results in an amino acid frameshift and creates a premature stop codon 15 amino acids downstream of the variant, p.Cys3233Trpfs*15. This sequence change is not anticipated to result in nonsense mediated decay, but does disrupt the c-terminal domain of the BRCA2 protein. This sequencing change has been described in the gnomAD database with a low population frequency of 0.006% (dbSNP rs1277986751). This variant has been reported in the heterozygous and the compound heterozygous states in individuals with breast cancer (PMIDs:25639900, 29875428, 29161300). However, family testing did not demonstrate consistent segregation of the this variant with breast or ovarian cancer (PMIDs:25639900). This variant in the compound heterozygous state with another pathogenic variant has been described in individuals with a mild form of Fanconi anemia (PMID: 25639900). Other truncating variants in this region and downstream of this variant have been determined to be pathogenic (PMID: 18607349, 18593900, 22711857, 17026620). Collectively these evidences indicate that, the c.9699_9702del sequence is pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10987855</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="397318" SubmissionDate="2015-03-11" DateLastUpdated="2022-12-24" DateCreated="2015-03-29">
        <ClinVarSubmissionID localKey="NM_000059.3(BRCA2):c.9699_9702delTATG" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000220562" DateUpdated="2022-12-24" DateCreated="2015-03-29" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-07-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Dominant Disease Classification criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/qikq0wz6/counsyl_autosomal_dominant_disease_classification_criteria_2015__v1_4_2_.pdf</URL>
            <CitationText>Counsyl Autosomal Dominant Disease Classification criteria (2015)</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Counsyl_2015_03_01</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1361614" SubmissionDate="2023-06-21" DateLastUpdated="2023-06-24" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702delTATG|MedGen:CN169374" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000695262" DateUpdated="2023-06-24" DateCreated="2018-03-17" Type="SCV" Version="7" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24549055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25863477</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26633542</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27352968</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27276934</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29161300</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29339979</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29922827</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29907814</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29997359</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30630528</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31658756</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29875428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31753525</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32393813</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33293522</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32939053</ID>
          </Citation>
          <Comment>Variant summary: BRCA2 c.9699_9702delTATG (p.Cys3233TrpfsX15) results in a premature termination codon located in the BRCA2 C-terminal domain encoded by exon 27 that contains a nuclear localization signal, interacts with RAD51 in a CDK-dependent manner, and is required for maintaining genomic stability after DNA damage. Truncations downstream of this position have been classified as pathogenic by our laboratory and cited in HBOC patients. 2/4 splicing prediction tools predict that this variant may strengthen a cryptic 3' splicing acceptor site, which may lead to alternative start of exon 27 and frameshift. However, no alternatively spliced transcripts were detected for this variant (Biswas_2020). This variant was predicted not to result in Nonsense-Mediated Decay and associated with stable mutant proteins (Rebbeck_2018). The variant allele was found at a frequency of 6.4e-05 in 250272 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer (6.4e-05 vs 0.00075), allowing no conclusion about variant significance. The variant, c.9699_9702delTATG, has been reported in the literature in individuals affected with Breast and Ovarian Cancer (example, Castera_2014, Rosenthal_2015, Kan_2015, Alemar_2017, Bunnell_2017, Rebbeck_2018, Palmero_2018, Delgado-Balderas_2018, Heramb_2018, Le Page_2019, Turner_2019, Olafsdottir_2020), medulloblastoma (Waszak_2018) and intraductal papillary mucinous neoplasms (Skaro_2019). At-least one patient carried this variant along with a second BRCA2 variant (c.8878C&gt;T, p.Gln2960X) and no associated phenotype of Fanconi Anemia (Alemar_2017). In our evaluation of this supporting literature, we conservatively ascertained at-least 11 transmissions of the variant allele and 4 transmissions of the reference allele to affected individuals in families with this variant. The ascertained penetrance of Hereditary Breast and Ovarian Cancer (0.44) due to this variant appears to be lower than expected allowing no firm conclusions from these data. Rosenthal_2015 evaluated the variant of interest and observed the variant in at least 1 Family with a suggested mild form of Fanconi Anemia. This family was ascertained because a female was diagnosed with breast cancer at 22 y/o and carried the variant of interest and another BRCA2 variant, c.145G&gt;T (p.Glu49X) believed to be in trans, although not confirmed. Her brother (15 y/o) who carried the same two variants (identical genotype) was indicated to have no symptoms at the time of publication. However, both siblings were reported to have had abnormal chromosome mitomycin C stress testing. The authors went on to state that they "detected this variant in 67 apparently unrelated individuals undergoing comprehensive analysis of BRCA1 and BRCA2, it has been seen in two individuals who also carry a pathogenic variant in BRCA1." The authors further evaluated the variant of interest in the Myriad database and found multiple relatives of probands that carried the variant of interest that were either affected or unaffected, along with affected individuals that did not carry the variant of interest. Therefore, the authors concluded that the variant of interest needs to be reported as a "special interpretation variant" and conclude "there is as yet no compelling hypothetical mechanism as to why BRCA2 c.9699_9702del is not causative of HBOC." "It is important to note that the variant of interest described here is yet proven to have absolutely no impact on cancer risk, although the available data in each case suggest that the risk falls far short of what is considered to be diagnostic of the associated clinical syndrome." Multiple co-occurrences with other pathogenic variants have been reported from databases and publications (Rosenthal_2015, Alemar_2017), providing supporting evidence for a benign role (UMD-BRCA1 c.3979C&gt;T, p.Gln1327X; BIC-BRCA1 c.3759_3760delTA, p.Lys1254fsX12; Alemar_2017-BRCA2 c.8878C&gt;T, p.Gln2960X; Rosenthal_2015-BRCA2 c.145G&gt;T, p.Glu49*, Le Page_2019-BRCA1 c.3759_3760del, p.Lys1254fs). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. At least one publication reports experimental evidence evaluating an impact on protein function (Biswas_2020). The most pronounced variant effect results in approximately 33% of wild type activity in ionizing radiation (IR) induced RAD51 foci formation in a Brca2 KO/KO mouse embryonic stem cell system. It was also able to rescue the lethality of Brca2 KO/KO ES cells at low levels. Multipple submitters including one expert panel (ENIGMA, classification dated 2016) and a consortium (CIMBA) have provided clinical-significance assessments for this variant to ClinVar after 2014. The classifications are conflicting with pathogenic (to include the expert panel), likely pathogenic, and VUS. Some submitters cite overlapping evidence utilized in the context of this evaluation. A follow-up with the expert panel regarding an updated classification (ENIGMA) is pending at the time of this re-evaluation (personal correspondence). Based on equivocal evidence of co-segregation with disease, presence with co-occurring BRCA2 variants in patients with and without features of Fanconi Anemia, and the emerging functional evidence as outlined above, the variant retained its classification as a special interpretation VUS-possibly pathogenic risk variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN169374" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10680216</SubmissionName>
          <SubmissionName>SUB11991162</SubmissionName>
          <SubmissionName>SUB13562035</SubmissionName>
          <SubmissionName>SUB8492518</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="121830" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2013-07-03">
        <ClinVarSubmissionID localKey="913911|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000073900" DateUpdated="2024-02-20" DateCreated="2013-07-03" Type="SCV" Version="13" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000219055" DateChanged="2016-01-29" Version="2" />
        </ReplacedList>
        <Classification DateLastEvaluated="2024-01-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29161300</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30716324</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17026620</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18593900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18607349</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22711857</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Cys3233Trpfs*15) in the BRCA2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 186 amino acid(s) of the BRCA2 protein. This variant is present in population databases (rs781465150, gnomAD 0.04%). This premature translational stop signal has been observed in individual(s) with clinical features of Fanconi anemia (Invitae). This finding is consistent with autosomal recessive inheritance and suggests that this variant contributes to disease. However, in two reported families, this variant occurred with a second pathogenic variant in individuals with early-onset breast cancer; both variants were also found in their healthy siblings, whose only features were abnormal cellular studies (PMID: 25639900). While this variant has been observed in individuals with breast, ovarian, pancreatic and brain cancer (PMID: 29161300, 29084914, 30716324, 29753700, Invitae), published data has shown inconsistent segregation with HBOC-associated cancers (PMID: 25639900). This suggests that this pathogenic variant may exhibit lower penetrance or an atypical clinical presentation (PMID: 25639900). ClinVar contains an entry for this variant (Variation ID: 38260). This variant disrupts a region of the BRCA2 protein in which other variant(s) (p.Gln3299Ilefs*29, p.Tyr3308*) have been determined to be pathogenic (PMID: 17026620, 18593900, 18607349, 22711857; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972347_32972350del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1570751" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="1897541|BRCA2-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000805800" DateUpdated="2024-03-16" DateCreated="2018-03-17" Type="SCV" Version="2" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.9699_9702delTATG variant is predicted to result in a frameshift and premature protein termination (p.Cys3233Trpfs*15). This variant has been reported in an individual with medulloblastoma (Waszak et al. 2018. PubMed ID: 29753700, Table S2, Donor ID MD-054), an individual with pancreatic cancer (Grant et al. 2015. PubMed ID: 25479140, Table S1), and in individuals with a personal and/or family history of breast and/or ovarian cancer (van der Hout et al. 2006. PubMed ID: 16683254, Table 5; CastÃ©ra et al. 2014. PubMed ID: 24549055, Table 1; Kang et al. 2015. PubMed ID: 25863477, Table 5; Bunnell et al. 2017. PubMed ID: 27276934, Table 3; Lilyquist et al. 2017. PubMed ID: 28888541. Table S7; Labidi-Galy et al. PubMed ID: 29084914, Table S2; Turner et al. 2019. PubMed ID: 29875428, Table 2; Delgado-Balderas et al. 2018. PubMed ID: 29997359, Table 1; Le Page et al. 2020. PubMed ID: 31753525, Table 1; Olafsdottir et al. 2020. PubMed ID: 32939053, Table S1). This variant has been reported along with a second truncating BRCA2 variant (c.9699_9702del, which was suspected to occur in trans) in an individual with early onset breast cancer and their unaffected sibling (Rosenthal et al. 2015. PubMed ID: 25639900, Table 1). Interestingly, both siblings had abnormal mitomycin C stress testing. This variant has also been observed in trans with a pathogenic BRCA2 missense variant in an individual with atypical Fanconi anemia (FA) and their unaffected sibling (Rosenthal et al. 2015. PubMed ID: 25639900, Table 1). It has also been reported to co-occur with a BRCA2 truncating variant in an additional individual with breast cancer at age 39, but no indication of FA (Alemar et al. 2017. PubMed ID: 29161300, Table S2). It has been reported in many unaffected relatives of individuals with breast and ovarian cancer and has been reported to co-occur with pathogenic BRCA1 variants in two unrelated individuals (Rosenthal et al. 2015. PubMed ID: 25639900). It has also been reported in individuals and families without histories of hereditary cancer and/or FA (Rudolf et al. 2016. PubMed ID: 27352968; Grzymski et al. 2020. PubMed ID: 32719484, Table S3). In vitro experimental studies and in silico models suggest this variant leads to the production of a truncated protein that may be partially defective in IR-induced RAD51 foci formation and in protecting replication fork stability (Biswas et al. 2020. PubMed ID: 33293522). This variant is reported in 0.040% of alleles in individuals of Latino descent in gnomAD and has also been reported in 0.08% of alleles in individuals from the Mexican population (FernÃ¡ndez-Lopez et al. 2019. PubMed ID: 30630528, Table S3). This variant has been reported as likely pathogenic for susceptibility to familial breast-ovarian cancer with suspected reduced penetrance by the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel (https://www.ncbi.nlm.nih.gov/clinvar/variation/38260/). Taken together, this variant is interpreted as likely pathogenic for hereditary cancer, however due to the higher than expected frequency and results of family history analysis, reduced penetrance is suspected. This variant is interpreted as likely pathogenic for autosomal recessive Fanconi anemia.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BRCA2-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
          <SubmissionName>SUB3589995</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9799118" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2024-06-09">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005049391" DateUpdated="2024-06-09" DateCreated="2024-06-09" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>WES_20231129_20240331</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7863045" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000059.4:c.9699_9702del|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004211784" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="90066" SubmissionDate="2013-06-26" DateLastUpdated="2014-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="SCRP_var_895" title="NM_000059.3:c.9699_9702delTATG AND Breast-ovarian cancer, familial 2" />
        <ClinVarAccession Accession="SCV000054451" DateUpdated="2014-09-27" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="Sharing Clinical Reports Project (SCRP)" OrgID="500037" OrganizationCategory="consortium" OrgAbbreviation="SCRP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2012-07-30">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="Penetrance">reduced penetrance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ClassificationHistory" dateValue="2011-08-29" integerValue="9">Pathogenic</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ClassificationHistory" dateValue="2012-03-01" integerValue="1">not provided</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <NumberTested>11</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles">11</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="nucleotide change">9927del4</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1120382" SubmissionDate="2017-04-18" DateLastUpdated="2017-05-07" DateCreated="2017-05-07">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000575748" DateUpdated="2017-05-07" DateCreated="2017-05-07" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-01-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2591501</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1140941" SubmissionDate="2017-08-04" DateLastUpdated="2016-01-31" DateCreated="2016-01-31">
        <ClinVarSubmissionID localKey="291340|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000588014" DateUpdated="2016-01-31" DateCreated="2016-01-31" Type="SCV" Version="1" SubmitterName="Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto" OrgID="506247" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-01-31">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000059.3:c.9699_9702delTATG</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972349_32972352delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>RMGL-WCRI-05152017</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1770157" SubmissionDate="2019-02-16" DateLastUpdated="2019-05-13" DateCreated="2019-05-13">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9697_9700del|Orphanet:ORPHA485382" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000902413" DateUpdated="2019-05-13" DateCreated="2019-05-13" Type="SCV" Version="1" SubmitterName="Center for Reproductive Medicine, Shandong Provincial Hospital Affiliated to Shandong University" OrgID="506889" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9697_9700del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA485382" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5181487</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2843775" SubmissionDate="2020-10-12" DateLastUpdated="2020-10-31" DateCreated="2020-10-31">
        <ClinVarSubmissionID localKey="CV_varv_228|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001440712" DateUpdated="2020-10-31" DateCreated="2020-10-31" Type="SCV" Version="1" SubmitterName="Institute of Human Genetics, University of Leipzig Medical Center" OrgID="506086" OrganizationCategory="clinic" OrgAbbreviation="UKL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>varv_082020</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2862824" SubmissionDate="2020-11-26" DateLastUpdated="2020-12-12" DateCreated="2020-12-12">
        <ClinVarSubmissionID localKey="NM_000059.4:c.9699_9702del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001449958" DateUpdated="2020-12-12" DateCreated="2020-12-12" Type="SCV" Version="1" SubmitterName="Clinical Genetics and Genomics, Karolinska University Hospital" OrgID="505315" OrganizationCategory="laboratory" OrgAbbreviation="KLINGEN-KUS" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-03-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8639822</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5043638" SubmissionDate="2022-10-06" DateLastUpdated="2022-10-15" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000059.4:c.9699_9702del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002579465" DateUpdated="2022-10-15" DateCreated="2022-10-15" Type="SCV" Version="1" SubmitterName="MGZ Medical Genetics Center" OrgID="255845" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80359775" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>ACMG criteria applied: PVS1, PM2_SUP</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB12035528</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="627272" SubmissionDate="2016-10-28" DateLastUpdated="2022-12-11" DateCreated="2016-11-05">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702del|OMIM:612555" submittedAssembly="hg18" />
        <ClinVarAccession Accession="SCV000328164" DateUpdated="2022-12-11" DateCreated="2016-11-05" Type="SCV" Version="4" SubmitterName="Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge" OrgID="505954" OrganizationCategory="consortium" OrgAbbreviation="CIMBA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CIMBA Mutation Classification guidelines May 2016</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/nhgqiuyb/cimba_mutation_classification_guidelines_may16.pdf</URL>
            <CitationText>CIMBA_Mutation_Classification_guidelines_May16.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="14" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>CIMBA_20161005</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1169403" SubmissionDate="2017-10-18" DateLastUpdated="2022-12-11" DateCreated="2017-05-07">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702del|MedGen:C2675520" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000605701" DateUpdated="2022-12-11" DateCreated="2017-05-07" Type="SCV" Version="3" SubmitterName="Department of Medical Genetics, Oslo University Hospital" OrgID="505260" OrganizationCategory="laboratory" OrgAbbreviation="AMG, OUS" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-01-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="12" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3136286</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4949332" SubmissionDate="2022-06-10" DateLastUpdated="2022-12-24" DateCreated="2022-06-18">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9699_9702del|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002526096" DateUpdated="2022-12-24" DateCreated="2022-06-18" Type="SCV" Version="2" SubmitterName="St. Jude Molecular Pathology, St. Jude Children's Research Hospital" OrgID="506672" OrganizationCategory="laboratory" OrgAbbreviation="SJCRH-MP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">St. Jude Assertion Criteria 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/0uggzi4w/st._jude_assertion_criteria_2020.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11592018</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2899978" SubmissionDate="2023-01-06" DateLastUpdated="2023-03-04" DateCreated="2021-01-26">
        <ClinVarSubmissionID localKey="3386209|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001471994" DateUpdated="2023-03-04" DateCreated="2021-01-26" Type="SCV" Version="3" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>The BRCA2 c.9699_c.9702delTATG; p.Cys3233TrpfsTer15 variant (rs80359775) has been described in individuals with breast cancer and individuals with a clinical diagnosis of hereditary breast and ovarian cancer (HBOC; Bunnell 2017, Rebbeck 2018, van der Hout 2006). Truncations occurring downstream of this position have been classified as pathogenic by our laboratory (c.96725dupA;p.Tyr3255fs, c.9924C&gt;G; p.Tyr3308Ter) and identified in HBOC patients (Alsop 2012, Tea 2014, van der Hout 2006, Waddell 2008). However, the c.9699_9702delTATG; p.Cys3233TrpfsTer15 variant has also been described in individuals who also carry an additional BRCA2 variant, without Fanconi anemia symptoms (Alemar 2017, Rosenthal 2015). The variant is present in the ClinVar database with discrepant classifications, but is classified as pathogenic by an expert panel (Variation ID: 38260). The variant is found in the Latino/Admixed American population with an allele frequency of 0.04% (14/35,226 alleles) in the Genome Aggregation Database. This variant results in a premature termination codon in the last exon of the BRCA2 gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated BRCA2 protein. Due to conflicting information, the clinical significance of the c.9699_c.9702delTATG; p.Cys3233TrpfsTer15 variant is uncertain at this time. References: Alemar B et al. Probands From Southern Brazil: Are International Testing Criteria Appropriate for This Specific Population? BRCA1 and BRCA2 Mutational Profile and Prevalence in Hereditary Breast and Ovarian Cancer (HBOC). PLoS One. 2017 Nov 21;12(11):e0187630. Alsop K et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 30:2654-2663. Bunnell AE et al. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. J Genet Couns. 2017 Feb;26(1):105-112. Rebbeck TR et al. Mutational Spectrum in a Worldwide Study of 29,700 Families With BRCA1 or BRCA2 Mutations. Hum Mutat. 2018 May;39(5):593-620. Rosenthal ET et al. Exceptions to the Rule: Case Studies in the Prediction of Pathogenicity for Genetic Variants in Hereditary Cancer Genes. Clin Genet. 2015 Dec;88(6):533-41. Tea MK et al. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer. Maturitas. 2014 Jan;77(1):68-72. van der Hout AH et al. A DGGE System for Comprehensive Mutation Screening of BRCA1 and BRCA2: Application in a Dutch Cancer Clinic Setting. Hum Mutat. 2006 Jul;27(7):654-66. Waddell N et al. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. PLoS Genet. 2008 4:e1000080.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/ythvkvge/arup_molecular_germline_variant_investigation_process_2021.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972349_32972352del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2897795" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2021-01-26">
        <ClinVarSubmissionID localKey="S4364|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001470467" DateUpdated="2024-01-06" DateCreated="2021-01-26" Type="SCV" Version="4" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29907814</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30720243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32719484</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32939053</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33293522</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29922827</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26633542</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24549055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33804961</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32853339</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33753322</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32482800</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27276934</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25863477</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27352968</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30716324</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32393813</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31753525</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31658756</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30630528</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29875428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29997359</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35260348</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35438911</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29161300</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29339979</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Comment>This variant alters the translational reading frame of the BRCA2 mRNA. However due to the location of the variant in the last exon of the gene, the premature termination of BRCA2 protein synthesis is possible but the effect on protein function is uncertain. In the published literature, this variant has been reported in individuals and families with breast and/or ovarian cancer (PMIDs: 35438911 (2022), 32939053 (2020), 31658756 (2019), 29997359 (2018), 29339979 (2018), 29084914 (2018), 29161300 (2017), 27276934 (2016), 16683254 (2006)), adenomatous polyposis (PMID: 33753322 (2021)), prostate cancer (PMIDs: 35260348 (2022), 32853339 (2021)), and in healthy individuals (PMIDs: 33804961 (2021), 32719484 (2020), 30720243 (2019), 29922827 (2018), 27276934 (2016)). Additionally, this variant is reported to occur in trans with known pathogenic BRCA variants in individuals with Fanconi Anemia (PMID: 25639900 (2015)). An experimental study's report regarding the impact of this variant on BRCA2 protein function was inconclusive (PMID: 33293522 (2020)). The frequency of this variant in the general population, 0.0004 (14/35226 chromosomes in Latino/Admixed American subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Based on the available information, we are unable to determine the clinical significance of this variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10813355</SubmissionName>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB8819638</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7928165" SubmissionDate="2024-02-05" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="BCLV000673|MedGen:C2675520" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004243879" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="BRCAlab, Lund University" OrgID="508740" OrganizationCategory="laboratory" OrgAbbreviation="BRCAlab" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-02">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972349_32972352del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BCLS000001</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1770886" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2019-05-20">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkQmFVfrNTm76AK3giwBAauY|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000902932" DateUpdated="2024-02-14" DateCreated="2019-05-20" Type="SCV" Version="4" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24549055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25479140</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25863477</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28637432</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28888541</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29084914</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29161300</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29339979</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29875428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33293522</ID>
          </Citation>
          <Comment>This variant deletes 4 nucleotides in exon 27 of the BRCA2 gene, creating a frameshift and premature translation stop signal in the last coding exon. This variant is also known as 9927del4 and c.9697_9700del. The mutant transcript is predicted to be expressed as a truncated protein lacking the C-terminal RAD51 interaction domain and nuclear localization signals. This variant has been reported to impact BRCA2 function in the rescue of cell viability and PARP-inhibitor sensitivity in BRCA2-deficient cells (PMID: 33293522). This variant has been reported in over ten individuals affected with breast, ovarian, and pancreatic cancer (PMID: 16683254, 25479140, 24549055, 25639900, 25863477, 28637432, 28888541, 29084914, 29161300, 29339979, 29875428; Color data). This variant, in trans with another pathogenic variant in the BRCA2 gene, has been reported in individuals showing clinical features of autosomal recessive Fanconi anemia (external communication, ClinVar SCV000073900.8). However, the variant has not shown consistent segregation with cancer in family studies and has also been observed biallelic with different BRCA2 pathogenic variants in several carriers without symptoms of Fanconi anemia (PMID: 25639900, 29161300; Color internal data). This variant has been identified in 17/281678 chromosomes in the general population by the Genome Aggregation Database (gnomAD). These findings suggest that this variant may show reduced penetrance compared to a traditional pathogenic BRCA2 variant. Based on available evidence this variant is classified as Likely Pathogenic with reduced penetrance.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9699_9702del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ColorClinVarSubmissionJune2021_SUB9834248</SubmissionName>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="304489" SubmissionDate="2024-04-19" DateLastUpdated="2024-05-01" DateCreated="2014-08-06">
        <ClinVarSubmissionID localKey="a4576|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000185974" DateUpdated="2024-05-01" DateCreated="2014-08-06" Type="SCV" Version="9" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18607349</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25639900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25863477</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29161300</ID>
          </Citation>
          <Comment>The c.9699_9702delTATG (p.C3233Wfs*15) alteration, located in exon 27 (coding exon 26) of the BRCA2 gene, consists of a deletion of 4 nucleotides from position 9699 to 9702, causing a translational frameshift with a predicted alternate stop codon after 15 amino acids. This alteration occurs at the 3' terminus of the BRCA2 gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 5.4% of the protein. However, premature stop codons are typically deleterious in nature, the impacted region is critical for protein function, and a significant portion of the protein is affected (Ambry internal data)._x000D_ _x000D_ However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA2 alteration. As risk estimates are unknown at this time, clinical correlation is advised. This alteration (also designated c.9699_9702del and 9927del4 in published literature) has been reported in hereditary breast and/or ovarian cancer families (van der Hout, 2006; Kang, 2015; Alemar, 2017). It has also been identified in multiple families with Fanconi Anemia in a compound heterozygous state with different pathogenic BRCA2 variants (Ambry internal data; external communication), including multiple families presenting with atypical (unusually mild) Fanconi Anemia (Rosenthal, 2015). This alteration occurs 5' to two nonsense mutations at Y3308* and E3309*, which have been shown to be deleterious in in vitro and in vivo functional assays utilizing mouse embryonic stem cells (Kuznetsov, 2008). Based on the available evidence, this alteration is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9699_9702delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>FinalAVA3AVA4ClinvarDepositThrough091523</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava4_1</SubmissionName>
          <SubmissionName>NovelandUpdateExomeDeposit_ExomeProgenyThrough080120</SubmissionName>
          <SubmissionName>exome clinvar deposit 2.18.18</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="7681135" SubmissionDate="2024-06-11" DateLastUpdated="2024-06-17" DateCreated="2023-11-11">
        <ClinVarSubmissionID localKey="597d0db5-c993-419b-8a7e-504098d8d901" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004101445" DateUpdated="2024-06-17" DateCreated="2023-11-11" Type="SCV" Version="2" SubmitterName="ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel, ClinGen" OrgID="509268" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-06-11">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Likely Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/597d0db5-c993-419b-8a7e-504098d8d901</URL>
          </Citation>
          <Comment>The c.9699_9702del variant in BRCA2 is a deletion of four nucleotides, predicted to encode a frameshift with consequent premature termination of the protein at codon 15 of the frameshift, or amino acid 3247 (p.Cys3233TrpfsTer15). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth &gt;=20) or gnomAD v3.1 (non-cancer subset, read depth &gt;=20) is 0.0002484 in the Latino/Admixed American population, which is above the ENIGMA BRCA1/2 VCEP threshold (&gt;0.0001) for BS1, and below the BA1 threshold (&gt;0.001) (BS1 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 7.08E-23 (based on Family History LR=7.08E-23), below the thresholds for Very strong benign evidence (LR &lt;0.00285) (BP5_Very strong met; Ambry internal contributor). Additional published family history analysis also reflects that this variant does not behave like other high risk variants (PMID: 25639900). Frameshift variant predicted to cause a premature stop codon that is predicted to escape nonsense mediated decay, however it is a truncation of a functionally important region (sequence upstream of BRCA2 p.Glu3309 is disrupted) (PVS1 met). The ENIGMA BRCA1/2 VCEP considered multiple lines of functional and clinical evidence to define exon-specific weights for PTC in BRCA2, and results indicate that strong evidence towards pathogenicity may be applied for a PTC variant in BRCA2 exon 27 (PTC occurs before p.T3310) (PM5_Strong (PTC)). Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 33293522) (PS3 met). This variant has been detected in 1 individual with phenotype consistent with BRCA2-Fanconi Anemia (FA). At least one clinical feature of FA (physical features, pathology findings and cancer diagnosis &lt;=5yr) and confirmed chromosome breakage, is seen in this individual. The individual was compound heterozygous for the variant and a pathogenic or likely pathogenic variant confirmed to be in trans. BRCA2:c.9699_9702del has also been detected in multiple individuals with phenotypic features consistent with FA but who did not meet our criteria for applying PM3. Total points equated to 2 (PM3 met; Ambry and Invitae internal contributors, PMID: 25639900). Due to the higher than expected frequency and results of family history analysis, this variant is considered likely pathogenic with suspected reduced penetrance. In summary, this variant meets the criteria to be classified as a Likely pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1, BP5_Very strong, PM5_Strong (PTC), PVS1, PS3, PM3).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CSpec BRCA1/2ACMG Rules Specifications V1.0</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xhzbw3jc/cspec_brca12acmg_rules_specifications_v1.0_2023-04-27.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000059.4(BRCA2):c.9699_9702del</Name>
            <Name>p.Cys3233fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.11:g.32398212_32398215del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0700269" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13960564</SubmissionName>
          <SubmissionName>SUB14527527</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7322129" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2023-04-23">
        <ClinVarSubmissionID localKey="128297|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003917277" DateUpdated="2024-07-15" DateCreated="2023-04-23" Type="SCV" Version="10" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>BRCA2: PM2, PS3:Moderate, PVS1:Moderate</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="T" referenceAllele="TTGTA" start="32972346" stop="32972350" variantLength="5" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="264598" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5043638" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1361614" TraitType="Disease" MappingType="XRef" MappingValue="CN169374" MappingRef="MedGen">
        <MedGen CUI="CN169374" Name="not specified" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1140941" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1770886" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="90066" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="304489" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1148747" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007254" MappingRef="MONDO">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7863045" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1169403" TraitType="Disease" MappingType="XRef" MappingValue="C2675520" MappingRef="MedGen">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2899978" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1770157" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA485382" MappingRef="Orphanet">
        <MedGen CUI="C5816691" Name="Genetic non-acquired premature ovarian failure" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1570751" TraitType="Disease" MappingType="Name" MappingValue="BRCA2-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239275" Name="BRCA2-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7681135" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0700269" MappingRef="MONDO">
        <MedGen CUI="CN377758" Name="BRCA2-related cancer predisposition" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2843775" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9799118" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4949332" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4054620" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="627272" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2897795" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="121830" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2862824" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7322129" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="397318" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7928165" TraitType="Disease" MappingType="XRef" MappingValue="C2675520" MappingRef="MedGen">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1120382" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="376493" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2023-03-03">SCV002023662</Accession>
        <Description>not specified</Description>
      </SCV>
      <SCV>
        <Accession Version="1" DateDeleted="2021-11-13">SCV001853467</Accession>
        <Description>not specified</Description>
      </SCV>
      <SCV>
        <Accession Version="2" DateDeleted="2024-01-25">SCV000301412</Accession>
        <Description>This variant has been recorded with an updated classification from the FDA-approved ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel.</Description>
      </SCV>
      <SCV>
        <Accession Version="4" DateDeleted="2024-04-22">SCV001181012</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

